Health Beats: Occupational Therapy with Jayme Stephen
In this edition of Carthage Area Hospital Health Beats, we sit down with occupational therapist Jayme Stephen. April is Occupational Therapy Month.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Project Purple takes on pancreatic cancer
HARTFORD, Conn. (WTNH) — Project Purple is taking on one of the most deadly cancers known, pancreatic cancer. Often called a 'silent killer,' this disease rarely shows symptoms until it's too late, contributing to a five-year survival rate in the single digits. Early detection is critical, yet no reliable screening method has existed until now. Thanks to a groundbreaking $700,000 grant announced last fall, Project Purple is six months into a transformative effort to change that reality. Dino Varrelli, founder and CEO of Project Purple, joined Good Morning Connecticut at 9 a.m. to discuss. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Local jail awarded grant to help inmates with addiction treatment
(WKBN) — The Mahoning County jail was named one of 13 recipients across the state and is set to receive $200,000 to help sheriffs prioritize addiction treatment for inmates, Attorney General Dave Yost announced Tuesday. This batch of grants, awarded to 13 jails serving a combined 18 counties, expands the program's reach to 26 counties statewide. With the latest payments, the total amount awarded since Yost announced the grants in March stands at more than $3.5 million. Previously, Trumbull County was awarded $250,000 in the same program. 'Each time I tour a jail with a sheriff who has received a grant, I am encouraged to hear how this funding is going to make a real difference in the fight against addiction,' Yost said. 'Although a jail is no substitute for a rehab center, these grants will aid recovery and support better outcomes for inmates struggling with substance abuse.' In all, Yost's office is offering $60 million in opioid settlement money over the next several years, with the goal of reducing fatal overdoses in Ohio's jails. The attorney general's Opioid Remediation Grant Program is awarding county jails up to $200,000 per year to hire a full-time addiction-services coordinator or contract with a company that provides such services to treat opioid and other addictions, helping inmates through detox and recovery. Additionally, any county that operates a jail can apply for a $50,000 grant to fund medications and supplies for inmates experiencing opioid withdrawal. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723
